<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03974932</url>
  </required_header>
  <id_info>
    <org_study_id>HTX-011-306</org_study_id>
    <nct_id>NCT03974932</nct_id>
  </id_info>
  <brief_title>Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen</brief_title>
  <official_title>A Phase 3b, Open-Label Study of HTX-011 as Part of a Scheduled Non-Opioid Multimodal Analgesic Regimen in Subjects Undergoing Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heron Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heron Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 3b, open-label single-arm study in which all subjects receive HTX-011 as part of a&#xD;
      scheduled non-opioid MMA regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 5, 2019</start_date>
  <completion_date type="Actual">January 7, 2021</completion_date>
  <primary_completion_date type="Actual">December 7, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean area under the curve (AUC) of the the visual analogue scale (VAS).</measure>
    <time_frame>12 through 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean AUC of VAS scores.</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean AUC of the NRS of pain intensity at rest (NRS-R).</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with severe pain.</measure>
    <time_frame>10 timepoints through 72 hours, and Day 11 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean total postoperative opioid consumption (in IV morphine milligram equivalents [MME]).</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are opioid-free.</measure>
    <time_frame>through 72 hours, and through Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are opioid-free through 72 hours who remain opioid-free through 72 hours who remain opioid-free.</measure>
    <time_frame>72 hours through Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to first opioid rescue medication.</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who do not receive an opioid prescription at discharge.</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who do not receive an opioid prescription between discharge and the Day 11 visit.</measure>
    <time_frame>72 hours through Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a score of &quot;good&quot; or better (&gt;1) pain control based on Patient Global Assessment (PGA).</measure>
    <time_frame>24 hours, 48 hours, 72 hours, Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to first ambulation postsurgery.</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects unable to participate in each rehabilitation session because of pain.</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who first achieve an MPADSS score â‰¥9.</measure>
    <time_frame>10 timepoints through 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are discharged home vs to a skilled nursing facility.</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean overall benefit of analgesia score (OBAS).</measure>
    <time_frame>24 hours, 48 hours, 72 hours, Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean total TSQM-9 score</measure>
    <time_frame>72 hours through Day 11</time_frame>
    <description>Treatment Satisfaction Questionnaire for Medication (9-question)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of occurrence of maximum concentration (Tmax)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTX-011 + MMA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTX-011 + MMA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTX-011 + MMA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTX-011 + MMA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-011</intervention_name>
    <description>Dual-acting local anesthetic. Dose 1.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>NSAID.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Analgesic.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>NSAID.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>+/- Bupivacaine HCl</intervention_name>
    <description>Local anesthetic.</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Luer Lock Applicator</intervention_name>
    <description>Applicator for instillation.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-011</intervention_name>
    <description>Dual-acting local anesthetic. Dose 2.</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is scheduled to undergo primary unilateral TKA under spinal anesthesia.&#xD;
&#xD;
          -  Has not previously undergone TKA in either knee.&#xD;
&#xD;
          -  Has an American Society of Anesthesiologists (ASA) Physical Status of I, II, or III.&#xD;
&#xD;
          -  Is able to walk at least 20 feet with optional use of a 4-legged walker for balance.&#xD;
&#xD;
          -  Female subjects are eligible only if not pregnant, not lactating, not planning to&#xD;
             become pregnant during the study, sterile; or is at least 2 years post-menopausal; or&#xD;
             is in a monogamous relationship with a partner who is surgically sterile; or using&#xD;
             acceptable contraceptives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a planned concurrent surgical procedure.&#xD;
&#xD;
          -  Has other pre-existing concurrent acute or chronic painful physical/restrictive&#xD;
             condition expected to require analgesic treatment in the postoperative period for&#xD;
             pain.&#xD;
&#xD;
          -  Has a contraindication or a known or suspected history of hypersensitivity or&#xD;
             clinically significant idiosyncratic reaction to required study medications.&#xD;
&#xD;
          -  Using or expected to use Factor IX Complex or anti-inhibitor coagulant concentrates&#xD;
             during the study.&#xD;
&#xD;
          -  Has known or suspected daily use of opioids for 7 or more consecutive days within the&#xD;
             previous 6 months.&#xD;
&#xD;
          -  Has taken NSAIDs within 10 days prior to the scheduled surgery with the exception of&#xD;
             subjects on low-dose (â‰¤100 mg) daily acetylsalicylic acid for cardioprotection.&#xD;
&#xD;
          -  Has taken opioids within 24 hours prior to the scheduled surgery (3 days for&#xD;
             long-acting).&#xD;
&#xD;
          -  Has been administered bupivacaine within 5 days prior to the scheduled surgery.&#xD;
&#xD;
          -  Has been administered any local anesthetic within 72 hours prior to the scheduled&#xD;
             surgery.&#xD;
&#xD;
          -  Has initiated treatment with medications within 1 month prior to study drug&#xD;
             administration that can impact pain control.&#xD;
&#xD;
          -  Has been administered systemic steroids within 5 half-lives or 10 days prior to&#xD;
             administration of study drug.&#xD;
&#xD;
          -  Received an investigational product or device in a clinical trial within 30 days or&#xD;
             within 5 elimination half lives.&#xD;
&#xD;
          -  Has a known or suspected history of drug abuse, a positive drug screen on the day of&#xD;
             surgery, or a recent history of alcohol abuse.&#xD;
&#xD;
          -  Has a medical condition such that, in the opinion of the Investigator, participating&#xD;
             in the study would pose a health risk to the subject or confound the postoperative&#xD;
             assessments.&#xD;
&#xD;
          -  Is currently undergoing treatment for hepatitis B, hepatitis C, or HIV.&#xD;
&#xD;
          -  Has uncontrolled anxiety, psychiatric, or neurological disorder that, in the opinion&#xD;
             of the Investigator, might interfere with study assessments.&#xD;
&#xD;
          -  Has acquired defective color vision or acute gastrointestinal ulcers, either of which&#xD;
             could interfere with scheduled study medications.&#xD;
&#xD;
          -  Has any chronic neuromuscular deficit of either femoral nerve function or thigh&#xD;
             musculature.&#xD;
&#xD;
          -  Has any chronic condition or disease that would compromise neurological or vascular&#xD;
             assessments.&#xD;
&#xD;
          -  Had a malignancy in the last year, with the exception of nonmetastatic basal cell or&#xD;
             squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Has undergone 3 or more surgeries within 12 months.&#xD;
&#xD;
          -  Has a body mass index (BMI) &gt;39 kg/m2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Helen Keller Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Clinical Research, LLC</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center, LLC</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Surgical Hospital</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plano Surgical Hospital</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials, LLC.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>March 7, 2021</last_update_submitted>
  <last_update_submitted_qc>March 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>total knee arthroplasty</keyword>
  <keyword>postoperative pain</keyword>
  <keyword>multimodal analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

